Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02130466
Title A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.
Indications

Advanced Solid Tumor

melanoma

Therapies

Dabrafenib + Trametinib

Pembrolizumab + Trametinib

Dabrafenib + Pembrolizumab

Dabrafenib + Pembrolizumab + Trametinib

Age Groups: adult | senior
Covered Countries

Additional content available in CKB BOOST